耐碳青霉烯类头孢他啶-阿维巴坦的肺炎克雷伯菌变体的患者间传播。
Patient-to-Patient Transmission of Klebsiella pneumoniae Carbapenemase Variants with Reduced Ceftazidime-Avibactam Susceptibility.
机构信息
Division of Infectious Diseases, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Department of Infection Prevention and Control, Froedtert Memorial Lutheran Hospital, Milwaukee, Wisconsin, USA.
出版信息
Antimicrob Agents Chemother. 2019 Sep 23;63(10). doi: 10.1128/AAC.00955-19. Print 2019 Oct.
Abstract
We report patient-to-patient transmission of isolates with reduced susceptibility to ceftazidime-avibactam due to production of KPC-40, a variant of KPC-3 with a two-amino-acid insertion in the Ω-loop region (L167_E168dup). The index patient had received a prolonged course of ceftazidime-avibactam therapy, whereas the second patient had not received the agent and still became colonized with the KPC-40-producing strain. The complex dynamics of KPC ( carbapenemase) described here highlight several key diagnostic and therapeutic considerations.
摘要
我们报告了 1 例因产生 KPC-40（KPC-3 的一种变体，在 Ω 环区有两个氨基酸插入（L167_E168dup））而对头孢他啶-阿维巴坦的敏感性降低的 分离株的患者间传播。该指数患者接受了长期的头孢他啶-阿维巴坦治疗，而第二位患者没有接受该药物，但仍被产生 KPC-40 的菌株定植。这里描述的复杂的 KPC（碳青霉烯酶）动力学突出了几个关键的诊断和治疗考虑因素。
相似文献
1
Patient-to-Patient Transmission of Klebsiella pneumoniae Carbapenemase Variants with Reduced Ceftazidime-Avibactam Susceptibility.耐碳青霉烯类头孢他啶-阿维巴坦的肺炎克雷伯菌变体的患者间传播。
Antimicrob Agents Chemother. 2019 Sep 23;63(10). doi: 10.1128/AAC.00955-19. Print 2019 Oct.
2
In vitro and in vivo bactericidal activity of ceftazidime-avibactam against Carbapenemase-producing .头孢他啶-阿维巴坦对产碳青霉烯酶的. 的体外和体内杀菌活性。
Antimicrob Resist Infect Control. 2018 Nov 21;7:142. doi: 10.1186/s13756-018-0435-9. eCollection 2018.
3
KPC-85, a carbapenemase-producing and ceftazidime-avibactam-resistant KPC-3 variant found in Klebsiella pneumoniae ST512 in the Netherlands.KPC-85，一种在荷兰肺炎克雷伯菌ST512中发现的产碳青霉烯酶且对头孢他啶-阿维巴坦耐药的KPC-3变体。
Int J Antimicrob Agents. 2024 Sep;64(3):107271. doi: 10.1016/j.ijantimicag.2024.107271. Epub 2024 Jul 11.
4
Carbapenemase-2 (KPC-2), Substitutions at Ambler Position Asp179, and Resistance to Ceftazidime-Avibactam: Unique Antibiotic-Resistant Phenotypes Emerge from β-Lactamase Protein Engineering.碳青霉烯酶 2（KPC-2），在 Ambler 位置 Asp179 的取代以及对头孢他啶-阿维巴坦的耐药性：β-内酰胺酶蛋白质工程产生独特的抗生素耐药表型。
mBio. 2017 Oct 31;8(5):e00528-17. doi: 10.1128/mBio.00528-17.
5
A Ceftazidime-Avibactam-Resistant and Carbapenem-Susceptible Klebsiella pneumoniae Strain Harboring Isolated in New York City.一株耐头孢他啶-阿维巴坦、碳青霉烯类敏感的肺炎克雷伯菌的分离与鉴定：来自纽约市的报告。
mSphere. 2020 Aug 26;5(4):e00775-20. doi: 10.1128/mSphere.00775-20.
6
Emergence of ceftazidime/avibactam resistance in carbapenem-resistant Klebsiella pneumoniae in China.中国耐碳青霉烯类肺炎克雷伯菌中头孢他啶/阿维巴坦耐药的出现。
Clin Microbiol Infect. 2020 Jan;26(1):124.e1-124.e4. doi: 10.1016/j.cmi.2019.08.020. Epub 2019 Sep 5.
7
Characterization of a KPC-84 harboring Klebsiella pneumoniae ST11 clinical isolate with ceftazidime-avibactam resistance.耐头孢他啶-阿维巴坦的产 KPC-84 肺炎克雷伯菌 ST11 临床分离株的特性。
Eur J Clin Microbiol Infect Dis. 2024 Oct;43(10):2029-2035. doi: 10.1007/s10096-024-04910-y. Epub 2024 Aug 7.
8
Klebsiella pneumoniae carbapenemase (KPC) producer resistant to ceftazidime-avibactam due to a deletion in the blaKPC3 gene.产碳青霉烯酶肺炎克雷伯菌（KPC），由于 blaKPC3 基因缺失对头孢他啶-阿维巴坦耐药。
Clin Microbiol Infect. 2020 Jul;26(7):946.e1-946.e3. doi: 10.1016/j.cmi.2020.02.007. Epub 2020 Feb 12.
9
First report of KPC variants conferring ceftazidime-avibactam resistance in Colombia: introducing KPC-197.哥伦比亚首次报道产碳青霉烯酶变种导致头孢他啶-阿维巴坦耐药：引入 KPC-197。
Microbiol Spectr. 2024 Jun 4;12(6):e0410523. doi: 10.1128/spectrum.04105-23. Epub 2024 May 3.
10
Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne Mutations during Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infections.耐碳青霉烯类肺炎克雷伯菌感染治疗期间因质粒介导的突变导致头孢他啶-阿维巴坦耐药的出现
Antimicrob Agents Chemother. 2017 Feb 23;61(3). doi: 10.1128/AAC.02097-16. Print 2017 Mar.
引用本文的文献
1
Characterization of a KPC-84 harboring Klebsiella pneumoniae ST11 clinical isolate with ceftazidime-avibactam resistance.耐头孢他啶-阿维巴坦的产 KPC-84 肺炎克雷伯菌 ST11 临床分离株的特性。
Eur J Clin Microbiol Infect Dis. 2024 Oct;43(10):2029-2035. doi: 10.1007/s10096-024-04910-y. Epub 2024 Aug 7.
2
carbapenemase variants: the new threat to global public health.碳青霉烯酶变体：对全球公共健康的新威胁。
Clin Microbiol Rev. 2023 Dec 20;36(4):e0000823. doi: 10.1128/cmr.00008-23. Epub 2023 Nov 8.
3
Epidemiology and In Vitro Activity of Ceftazidime/Avibactam, Meropenem/Vaborbactam and Imipenem/Relebactam against -Producing Collected from Bacteremic Patients, 2018 to 2020.2018年至2020年从菌血症患者中分离出的产碳青霉烯酶菌株对头孢他啶/阿维巴坦、美罗培南/瓦博巴坦和亚胺培南/瑞来巴坦的流行病学及体外活性研究
Antibiotics (Basel). 2022 Nov 14;11(11):1621. doi: 10.3390/antibiotics11111621.
4
Mechanisms of Resistance Development to Imipenem-Relebactam in KPC-Producing Klebsiella pneumoniae.产碳青霉烯酶肺炎克雷伯菌对亚胺培南-雷巴坦耐药机制的研究。
Antimicrob Agents Chemother. 2022 Oct 18;66(10):e0091822. doi: 10.1128/aac.00918-22. Epub 2022 Sep 26.
5
Klebsiella pneumoniae Carbapenemase Variants Resistant to Ceftazidime-Avibactam: an Evolutionary Overview.耐头孢他啶-阿维巴坦的肺炎克雷伯菌碳青霉烯酶变异体：进化概述。
Antimicrob Agents Chemother. 2022 Sep 20;66(9):e0044722. doi: 10.1128/aac.00447-22. Epub 2022 Aug 18.
6
A Two Amino Acid Duplication, L167E168, in the Ω-Loop Drastically Decreases Carbapenemase Activity of KPC-53, a Natural Class A β-Lactamase.L167E168 双氨基酸重复导致 Ω 环结构改变，极大降低 KPC-53 （一种天然型 A 类β-内酰胺酶）碳青霉烯酶活性
Antimicrob Agents Chemother. 2022 Jun 21;66(6):e0240221. doi: 10.1128/aac.02402-21. Epub 2022 Jun 1.
7
Successful Treatment of Bloodstream Infection due to a KPC-Producing Klebsiella Pneumoniae Resistant to Imipenem/Relebactam in a Hematological Patient.成功治疗一名血液系统疾病患者由产KPC且对亚胺培南/瑞来巴坦耐药的肺炎克雷伯菌引起的血流感染
Microorganisms. 2022 Apr 5;10(4):778. doi: 10.3390/microorganisms10040778.
8
Modelling of the transmission dynamics of carbapenem-resistant Klebsiella pneumoniae in hospitals and design of control strategies.医院碳青霉烯类耐药肺炎克雷伯菌传播动力学建模与控制策略设计。
Sci Rep. 2022 Mar 9;12(1):3805. doi: 10.1038/s41598-022-07728-w.
9
Ceftazidime/Avibactam-Resistant subsp. Isolates in a Tertiary Italian Hospital: Identification of a New Mutation of the Carbapenemase Type 3 (KPC-3) Gene Conferring Ceftazidime/Avibactam Resistance.意大利一家三级医院中对头孢他啶/阿维巴坦耐药的亚种分离株：鉴定一种导致头孢他啶/阿维巴坦耐药的新型3型碳青霉烯酶（KPC-3）基因变异
Microorganisms. 2021 Nov 15;9(11):2356. doi: 10.3390/microorganisms9112356.
10
KPC-53, a KPC-3 Variant of Clinical Origin Associated with Reduced Susceptibility to Ceftazidime-Avibactam.KPC-53，一种源自临床的KPC-3变体，对头孢他啶-阿维巴坦敏感性降低。
Antimicrob Agents Chemother. 2020 Dec 16;65(1). doi: 10.1128/AAC.01429-20.
本文引用的文献
1
Use of a cohorting-unit and systematic surveillance cultures to control a Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae outbreak.使用群体单元和系统监测培养物来控制产碳青霉烯酶肠杆菌科（KPC）爆发。
Infect Control Hosp Epidemiol. 2019 Jul;40(7):767-773. doi: 10.1017/ice.2019.99. Epub 2019 May 14.
2
Emergence of Enterobacteriaceae co-producing CTX-M-15, ArmA and PMQR in Poland.波兰产 CTX-M-15、ArmA 和 PMQR 的肠杆菌科的出现。
Adv Clin Exp Med. 2019 Feb;28(2):249-254. doi: 10.17219/acem/94165.
3
Carbapenemase-2 (KPC-2), Substitutions at Ambler Position Asp179, and Resistance to Ceftazidime-Avibactam: Unique Antibiotic-Resistant Phenotypes Emerge from β-Lactamase Protein Engineering.碳青霉烯酶 2（KPC-2），在 Ambler 位置 Asp179 的取代以及对头孢他啶-阿维巴坦的耐药性：β-内酰胺酶蛋白质工程产生独特的抗生素耐药表型。
mBio. 2017 Oct 31;8(5):e00528-17. doi: 10.1128/mBio.00528-17.
4
Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae.多黏菌素与头孢他啶-阿维巴坦治疗碳青霉烯类耐药肠杆菌科细菌感染。
Clin Infect Dis. 2018 Jan 6;66(2):163-171. doi: 10.1093/cid/cix783.
5
Unicycler: Resolving bacterial genome assemblies from short and long sequencing reads.单轮循环器：从短读长和长读长测序数据中解析细菌基因组组装结果
PLoS Comput Biol. 2017 Jun 8;13(6):e1005595. doi: 10.1371/journal.pcbi.1005595. eCollection 2017 Jun.
6
Mutations in That Confer Ceftazidime-Avibactam Resistance Encode Novel KPC-3 Variants That Function as Extended-Spectrum β-Lactamases.赋予头孢他啶-阿维巴坦耐药性的突变编码新型KPC-3变体，其作为超广谱β-内酰胺酶发挥作用。
Antimicrob Agents Chemother. 2017 Apr 24;61(5). doi: 10.1128/AAC.02534-16. Print 2017 May.
7
Genomic Characterization of Two KPC-Producing Klebsiella Isolates Collected in 1997 in New York City.1997年在纽约市采集的两株产KPC的克雷伯菌分离株的基因组特征分析
Antimicrob Agents Chemother. 2017 Mar 24;61(4). doi: 10.1128/AAC.02458-16. Print 2017 Apr.
8
Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne Mutations during Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infections.耐碳青霉烯类肺炎克雷伯菌感染治疗期间因质粒介导的突变导致头孢他啶-阿维巴坦耐药的出现
Antimicrob Agents Chemother. 2017 Feb 23;61(3). doi: 10.1128/AAC.02097-16. Print 2017 Mar.
9
Comprehensive Genome Analysis of Carbapenemase-Producing Enterobacter spp.: New Insights into Phylogeny, Population Structure, and Resistance Mechanisms.产碳青霉烯酶肠杆菌属的全基因组分析：系统发育、种群结构和耐药机制的新见解
mBio. 2016 Dec 13;7(6):e02093-16. doi: 10.1128/mBio.02093-16.
10
Microbiological features of KPC-producing Enterobacter isolates identified in a U.S. hospital system.在美国一家医院系统中鉴定出的产KPC肠杆菌分离株的微生物学特征。
Diagn Microbiol Infect Dis. 2014 Oct;80(2):154-8. doi: 10.1016/j.diagmicrobio.2014.06.010. Epub 2014 Jun 23.
Zotero 插件